• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Pasithea Therapeutics Corp.

    5/12/25 10:07:31 AM ET
    $KTTA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $KTTA alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    Pasithea Therapeutics Corp.

    (Name of Issuer)


    Common Stock, $0.0001 par value per share

    (Title of Class of Securities)


    70261F202

    (CUSIP Number)


    05/06/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    70261F202


    1Names of Reporting Persons

    CVI Investments, Inc.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    627,319.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    627,319.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    627,319.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.9 %
    12Type of Reporting Person (See Instructions)

    CO

    Comment for Type of Reporting Person:  With respect to Row 6 and Row 8 above, Heights Capital Management, Inc. is the investment manager to CVI Investments, Inc. and as such may exercise voting and dispositive power over the shares reported as beneficially owned by CVI Investments, Inc. herein.


    SCHEDULE 13G

    CUSIP No.
    70261F202


    1Names of Reporting Persons

    Heights Capital Management, Inc.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    627,319.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    627,319.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    627,319.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.9 %
    12Type of Reporting Person (See Instructions)

    CO

    Comment for Type of Reporting Person:  With respect to Row 6 and Row 8 above, Heights Capital Management, Inc. is the investment manager to CVI Investments, Inc. and as such may exercise voting and dispositive power over the shares reported as beneficially owned by CVI Investments, Inc. herein.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Pasithea Therapeutics Corp.
    (b)Address of issuer's principal executive offices:

    1111 Lincoln Road, Suite 500, Miami Beach, FL 33139
    Item 2. 
    (a)Name of person filing:

    This statement is filed by the entities listed below, who are collectively referred to herein as "Reporting Persons," with respect to the shares of common stock of Pasithea Therapeutics Corp. (the "Company"), $0.0001 par value per share (the "Shares"). (i) CVI Investments, Inc. (ii) Heights Capital Management, Inc.
    (b)Address or principal business office or, if none, residence:

    The address of the principal business office of CVI Investments, Inc. is: P.O. Box 309GT Ugland House South Church Street George Town Grand Cayman KY1-1104 Cayman Islands The address of the principal business office of Heights Capital Management, Inc. is: 101 California Street, Suite 3250 San Francisco, California 94111
    (c)Citizenship:

    Citizenship is set forth in Row 4 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.
    (d)Title of class of securities:

    Common Stock, $0.0001 par value per share
    (e)CUSIP No.:

    70261F202
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    The information required by this Item 4(a) is set forth in Row 9 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person. The number of Shares reported as beneficially owned consists of (i) 400,000 Shares, and (ii) Shares issuable upon the exercise of pre-funded warrants, Series C Common Warrants, and Series D Common Warrants to purchase Shares (together, the "Warrants"). The Warrants are not exercisable to the extent that the total number of Shares then beneficially owned by a Reporting Person and its affiliates and any other persons whose beneficial ownership of Shares would be aggregated with such Reporting Person for purposes of Section 13(d) of the Exchange Act, would exceed 9.99%. The Company's Prospectus (Registration No. 333-286889), filed on May 7, 2025, indicates there were 6,052,147 Shares (excluding Shares underlying the Warrants) outstanding as of the completion of the offering of the Shares referred to therein.
    (b)Percent of class:

    9.9  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    The information required by this Item 4(c)(i) is set forth in Row 5 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.

     (ii) Shared power to vote or to direct the vote:

    The information required by this Item 4(c)(ii) is set forth in Row 6 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person. Heights Capital Management, Inc., which serves as the investment manager to CVI Investments, Inc., may be deemed to be the beneficial owner of all Shares owned by CVI Investments, Inc. Each of the Reporting Persons hereby disclaims any beneficial ownership of any such Shares, except for their pecuniary interest therein.

     (iii) Sole power to dispose or to direct the disposition of:

    The information required by this Item 4(c)(iii) is set forth in Row 7 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.

     (iv) Shared power to dispose or to direct the disposition of:

    The information required by this Item 4(c)(iv) is set forth in Row 8 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person. Heights Capital Management, Inc., which serves as the investment manager to CVI Investments, Inc., may be deemed to be the beneficial owner of all Shares owned by CVI Investments, Inc. Each of the Reporting Persons hereby disclaims any beneficial ownership of any such Shares, except for their pecuniary interest therein.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    CVI Investments, Inc.
     
    Signature:/s/ Brian Sopinsky
    Name/Title:Brian Sopinsky, Secretary of Heights Capital Management, Inc.
    Date:05/12/2025
     
    Heights Capital Management, Inc.
     
    Signature:/s/ Brian Sopinsky
    Name/Title:Brian Sopinsky, Secretary
    Date:05/12/2025

    Comments accompanying signature:  Heights Capital Management, Inc. serves as authorized agent of CVI Investments, Inc. pursuant to a Limited Power of Attorney, a copy of which is attached as Exhibit I hereto.
    Exhibit Information

    EXHIBIT INDEX EXHIBIT DESCRIPTION ________ ________ I Limited Power of Attorney II Joint Filing Agreement

    Get the next $KTTA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $KTTA

    DatePrice TargetRatingAnalyst
    12/14/2021$3.25Buy
    EF Hutton
    More analyst ratings

    $KTTA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • EF Hutton initiated coverage on Pasithea Therapeutics with a new price target

      EF Hutton initiated coverage of Pasithea Therapeutics with a rating of Buy and set a new price target of $3.25

      12/14/21 8:32:07 AM ET
      $KTTA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KTTA
    Financials

    Live finance-specific insights

    See more
    • Pasithea Therapeutics Acquires AlloMek Therapeutics

      -- Expands CNS Product Portfolio with Addition of CIP-137401, a Macrocyclic, Next-Generation MEK Inhibitor -- Plans to File IND Application with the FDA to Enter the Clinic in 2H 2023 -- Plans to Initiate a Phase 1 Clinical Trial in the U.S. for Neurofibromatosis Type 1 (NF1) -- Management to Host an Investor Webcast Today at 9 a.m. ET MIAMI BEACH, Fla., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ:KTTA) ("Pasithea" or the "Company"), a biotechnology company focused on the discovery, research and development of innovative treatments for central nervous system (CNS) disorders, today announced that it acquired AlloMek Therapeutics, LLC ("AlloMek"), a privately-he

      10/12/22 8:00:00 AM ET
      $KTTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pasithea Therapeutics Acquires Alpha-5 Integrin, LLC

      - Alpha-5 is a potentially first-in-class monoclonal antibody for the treatment of amyotrophic lateral sclerosis (ALS) and other neurological diseases -- Expands pipeline across Pasithea's core therapeutic areas to drive enhanced growth -- Closing consideration of 3.26 million shares of Pasithea common stock -- Pasithea to hold a webcast on June 22 at 9 a.m. ET to discuss the transaction - MIAMI BEACH, Fla., June 22, 2022 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ:KTTA) ("Pasithea" or the "Company"), today announced its acquisition of Alpha-5 integrin, LLC ("Alpha-5"), a privately-held preclinical-stage company developing a monoclonal antibody (mAbs) for the treatment of am

      6/22/22 8:00:00 AM ET
      $KTTA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KTTA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Marques Tiago sold $792 worth of shares (960 units at $0.82), decreasing direct ownership by 2% to 40,001 units (SEC Form 4)

      4 - Pasithea Therapeutics Corp. (0001841330) (Issuer)

      5/14/25 9:55:17 PM ET
      $KTTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Novak Alfred J was granted 3,500 shares (SEC Form 4)

      4 - Pasithea Therapeutics Corp. (0001841330) (Issuer)

      6/14/24 5:25:21 PM ET
      $KTTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Marques Tiago (Amendment)

      4/A - Pasithea Therapeutics Corp. (0001841330) (Issuer)

      4/5/24 9:45:31 PM ET
      $KTTA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KTTA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Pasithea Therapeutics Announces Initiation of Phase 1/1B Study of PAS-004 in Adult NF1 Patients and Activation of First Clinical Trial Site

      -- First patient expected to be dosed during Q2 2025 ---- Trial will evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy in both plexiform neurofibromas and cutaneous neurofibromas ---- Starting dose of 4mg tablet QD (once daily) ---- First trial site in Australia. Four additional sites planned for Australia, South Korea, and U.S. –-- Australian R&D Tax Incentive refund of up to 48.5% of eligible study-related costs expected -- MIAMI, May 14, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ:KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor today ann

      5/14/25 7:02:00 AM ET
      $KTTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pasithea Therapeutics Announces Closing of $5 Million Public Offering

      MIAMI, May 07, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics, Corp. ("Pasithea," or the "Company") (NASDAQ:KTTA, KTTAW)), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, for the treatment of neurofibromatosis type 1 (NF1) and other cancer indications, today announced the closing of its previously announced public offering of 3,571,428 shares of its common stock (or pre-funded warrants in lieu thereof) and accompanying Series C warrants to purchase up to 3,571,428 shares of common stock and Series D warrants to purchase up to 3,571,428 shares of common stock, at a combined offering price of $1.40 per share of common stock (or per pre-

      5/7/25 5:00:00 PM ET
      $KTTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pasithea Therapeutics Announces Pricing of $5 Million Public Offering

      MIAMI, May 06, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics, Corp. ("Pasithea," or the "Company") (NASDAQ:KTTA, KTTAW)), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, for the treatment of neurofibromatosis type 1 (NF1) and other cancer indications, today announced the pricing of a public offering of 3,571,428 shares of the Company's common stock (or pre-funded warrants in lieu thereof) and accompanying Series C warrants to purchase up to 3,571,428 shares of common stock and Series D warrants to purchase up to 3,571,428 shares of common stock, at a combined offering price of $1.40 per share of common stock (or per pre-funded warran

      5/6/25 11:10:00 AM ET
      $KTTA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KTTA
    SEC Filings

    See more
    • SEC Form SCHEDULE 13G filed by Pasithea Therapeutics Corp.

      SCHEDULE 13G - Pasithea Therapeutics Corp. (0001841330) (Subject)

      5/12/25 4:08:40 PM ET
      $KTTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SCHEDULE 13G filed by Pasithea Therapeutics Corp.

      SCHEDULE 13G - Pasithea Therapeutics Corp. (0001841330) (Subject)

      5/12/25 10:07:31 AM ET
      $KTTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pasithea Therapeutics Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Pasithea Therapeutics Corp. (0001841330) (Filer)

      5/7/25 5:18:47 PM ET
      $KTTA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KTTA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Pasithea Therapeutics Corp.

      SC 13G - Pasithea Therapeutics Corp. (0001841330) (Subject)

      11/14/24 3:32:41 PM ET
      $KTTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Pasithea Therapeutics Corp. (Amendment)

      SC 13G/A - Pasithea Therapeutics Corp. (0001841330) (Subject)

      1/13/23 8:02:14 AM ET
      $KTTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Pasithea Therapeutics Corp. (Amendment)

      SC 13D/A - Pasithea Therapeutics Corp. (0001841330) (Subject)

      1/10/23 3:55:25 PM ET
      $KTTA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KTTA
    Leadership Updates

    Live Leadership Updates

    See more
    • Pasithea Therapeutics Announces Appointment of Dr. Rebecca Brown to its Scientific Advisory Board

      MIAMI, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ:KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, for the treatment of neurofibromatosis type 1 (NF1) and other indications, announced today that Rebecca Brown, M.D., Ph.D. has been appointed as a member of the Company's Scientific Advisory Board. Dr. Brown is currently Director of the Neurofibromatosis Clinic at The Mount Sinai Hospital and Assistant Professor in the Department of Neurology (Division of Neuro-Oncology), Internal Medicine, and Neurosurgery at the institution. Dr. Brown will contribute scientific insights

      9/3/24 8:02:00 AM ET
      $KTTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pasithea Therapeutics Announces Results from 2023 Annual Meeting

      SOUTH SAN FRANCISCO, Calif. and MIAMI, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. ("Pasithea" or the "Company") (NASDAQ:KTTA), today announced that it held its annual meeting of stockholders (the "Annual Meeting") on December 19, 2023. Over 70% of the Company's shares of common stock were represented at the Annual Meeting. More than 95% of shares voted were cast "for" the election of directors (Proposal 1), and over 85% "for" Proposals 2, 3 and 6 (collectively, the "Approved Proposals"). The Approved Proposals related to the following matters: appointment of the Company's proposed slate of directors;-  Dr. Tiago Reis Marques;-  Prof. Larry Steinman;-  Simon Dume

      12/19/23 5:19:00 PM ET
      $KTTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pasithea Therapeutics Appoints Life Sciences and Health Care Executive Alfred J. Novak to its Board of Directors

      MIAMI BEACH, Fla., Sept. 20, 2022 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ:KTTA) ("Pasithea" or the "Company"), a biotechnology company focused on the discovery, research and development of new and effective treatments for central nervous system ("CNS") disorders, today announced that Alfred J. Novak was appointed to its Board of Directors (the "Board"). Mr. Novak replaces Dr. Yassine Bendiabdallah, who stepped down from the Board on September 14, 2022. Mr. Novak has broad operating experience as a Chief Executive Officer and Chief Financial Officer and has served on the boards of several pharmaceutical and medical device companies. Mr. Novak brings financial acumen and ext

      9/20/22 8:00:00 AM ET
      $KTTA
      Biotechnology: Pharmaceutical Preparations
      Health Care